Department of Dermatology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
Int J Biol Sci. 2013 Jun 12;9(6):564-77. doi: 10.7150/ijbs.5425. Print 2013.
To construct short hairpin RNAs (shRNAs) and miR30-based shRNAs against heparanase (HPSE) to compare their safety and their effects on HPSE down-modulation in vitro and in vivo to develop a more ideal therapeutic RNA interference (RNAi) vector targeting HPSE.
First, we constructed shRNAs and miR30-based shRNAs against HPSE (HPSE-shRNAs and HPSE-miRNAs) and packed them into lentiviral vectors. Next, we observed the effects of the shRNAs on knockdown for HPSE expression, adhesion, migration and invasion abilities in human malignant melanoma A375 cells in vitro. Furthermore, we compared the effects of the shRNAs on melanoma growth, metastasis and safety in xenograft models.
Our data showed that these artificial miRNAs targeting HPSE could be effective RNAi agents mediated by Pol II promoters in vitro and in vivo, although these miRNAs were not more potent than the HPSE-shRNAs. It was noted that obvious lung injuries, rarely revealed previously, as well as hepatotoxicity could be caused by lentivirus-mediated shRNAs (LV shRNAs) rather than lentivirus-mediated miRNAs (LV miRNAs) in vivo. Furthermore, enhanced expression of pro-inflammatory cytokines IL-6 and TGF-β1 and endogenous mmu-miR-21a-5p were detected in lung tissues of shRNAs groups, whereas the expression of mmu-let-7a-5p, mmu-let-7b-5p and mmu-let-7c-5p were down-regulated.
These findings suggest that artificial miRNAs display an improved safety profile of lowered lung injury or hepatotoxicity relative to shRNAs in vivo. The mechanism of lung injuries caused by shRNAs may be correlated with changes of endogenous miRNAs in the lung. Our data here increase the flexibility of a miRNA-based RNAi system for functional genomic and gene therapy applications.
构建针对乙酰肝素酶(HPSE)的短发夹 RNA(shRNA)和 miR30 基 shRNA,比较其安全性及其在体外和体内下调 HPSE 的效果,以开发更理想的针对 HPSE 的治疗性 RNA 干扰(RNAi)载体。
首先,我们构建了针对 HPSE 的 shRNA 和 miR30 基 shRNA(HPSE-shRNA 和 HPSE-miRNA),并将其包装到慢病毒载体中。然后,我们观察了 shRNA 对体外人恶性黑色素瘤 A375 细胞中 HPSE 表达、黏附、迁移和侵袭能力的下调作用。此外,我们比较了 shRNA 对异种移植模型中黑色素瘤生长、转移和安全性的影响。
我们的数据表明,这些针对 HPSE 的人工 miRNA 可以作为 Pol II 启动子介导的体外和体内有效的 RNAi 试剂,尽管这些 miRNA 并不比 HPSE-shRNA 更有效。值得注意的是,体内慢病毒介导的 shRNA(LV shRNA)而不是慢病毒介导的 miRNA(LV miRNA)可能导致明显的肺部损伤,这是以前很少发现的,并且还可能导致肝毒性。此外,在 shRNA 组的肺组织中检测到促炎细胞因子 IL-6 和 TGF-β1 以及内源性 mmu-miR-21a-5p 的表达增强,而 mmu-let-7a-5p、mmu-let-7b-5p 和 mmu-let-7c-5p 的表达下调。
这些发现表明,与体内 shRNA 相比,人工 miRNA 显示出改善的安全性,降低了肺部损伤或肝毒性。shRNA 引起肺部损伤的机制可能与肺部内源性 miRNA 的变化有关。我们这里的数据增加了基于 miRNA 的 RNAi 系统在功能基因组和基因治疗应用中的灵活性。